Clinical trial · no report yet · Phase 3
RASolute 309
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- NCT07805954 ↗
- Recruiting
- Revolution Medicines, Inc.
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 11 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma
- Interventions
- daraxonrasib; gemcitabine; nab-paclitaxel; zoldonrasib
- Arms
- Arm A: daraxonrasib + zoldonrasib · Experimental
- Arm B: gemcitabine and nab-paclitaxel · Experimental
- Enrollment
- 400 (estimated)
- Primary outcomes
- Progression free survival (PFS)
- Overall survival (OS)
- Sponsor
- Revolution Medicines, Inc.
- Start
- Aug 28, 2026
- Primary completion
- Mar 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07805954 · updated Oct 16, 2026